Xconomy article on Arcturus Therapeutics, Inc. GEN article on Arcturus Therapeutics Inc. Union Tribune article on Arcturus Therapeutics Inc. Most of those COVID-19 vaccine candidates that you hear so much about require two doses, typically administered several weeks apart. About Arcturus Therapeutics Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA medicines and vaccines … Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study “Looking beyond that, into the (next) phase, Arcturus is hoping that we’ll be one of the top-tier vaccine candidates to manage COVID-19.”. Arcturus Therapeutics has built a multicultural team, based in San Diego, CA, USA, We have an exciting COVID-19 vaccine candidate that we hope will make a positive difference in the pandemic, See our team describe what it means for them to help get a vaccine to protect people around the world-no matter where you are from, https://arcturusrx.com/wp-content/uploads/2020/07/JoePayne_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/MaherA_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_BelleBao.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/BelleBao_LanguageProficiency__V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_HowardYu.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/HowardYu_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_YurongGuo.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/YurongGuo_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_XuefengGuo.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/XuefengGuo_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/MikeHodges_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/NedaSafarzadeh_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/NadjaEl-mecharrafie_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/LisaKieweg-Thompson_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_NoaScott.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/NoaScott_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_TamarGrossman.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/TamarGrossman_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/PriyaKarmali_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_CristianoSacchetti.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/CristianoSacchetti_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/thumbnail_GiulioCattarossi.jpg,https://arcturusrx.com/wp-content/uploads/2020/07/GiulioCattarossi_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/09/Kiyoshi_Tachikawa_v2.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/JaeHeonKim_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/RamonDiazTrelles_LanguageProficiency_V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/CarlosPerezGarcia_LanguageProficiency__V3_1.mp4, https://arcturusrx.com/wp-content/uploads/2020/07/HannahHuynh_LanguageProficiency_V3_1.mp4, link,https://ir.arcturusrx.com/static-files/198c6d28-bb6b-4162-a7a6-5854a0fd2d6c, video,https://arcturusrx.com/wp-content/themes/rewalk-parent/videos/Arcturus_fin_lunar_COVID_19.mp4, Arcturus Therapeutics Announces New Appointments to its Board of Directors and Scientific Advisory Board, Arcturus Therapeutics Raises $1.3 Million in Series Seed Funding, With $1.3M in Seed Funding, Arcturus Adds to RNAi Hub in San Diego, RNAi therapeutics startup sets up shop at Janssen labs, closes $1.3M seed round, Janssen Labs-based Arcturus gets $1.3M boost for RNAi delivery tech, Startup Arcturus Pulls in $1.3M in Seed Money amid Renewed Interest in RNAi, Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina Biotech, Arcturus Therapeutics Acquires Cutting-Edge UNA Patent Estate from Marina, San Diego upstart acquires RNA tech from cash-strapped Marina Biotech, San Diego Life Sciences Roundup: Vical, Fate, Arcturus, and More, Arcturus Therapeutics Acquires Patent Portfolio from Marina Biotech, Marina Sells UNA Patent Estate to Arcturus as It Looks to Resume Operations, GenomeWeb Acturus Closes $5M Series A Round, Aims for Clinic in '15 with RNAi Drug, RNAi firm raises $5M to develop and deliver drugs that turn off disease-causing genes, Arcturus Therapeutics Raises $5 Million in Series A Funding to Maintain its Momentum in Nominating Lead Clinical Candidate in 2014, San Diego's Arcturus Raises $5M for 'Best-in-Class' RNAi Technology, Arcturus rakes in $5M to back RNAi tech, nanoparticle delivery, Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014, Arcturus Therapeutics, Inc. Shares in Arcturus closed at $105.45 Thursday, up $16.40 for the day. San Diego’s Christmas week weather to start off warm then quickly turn cool, Moderate Santa Ana winds will raise wildfire risk on Wednesday, Losses continue to mount at Del Mar Fairgrounds, Entertainment contracts cancelled for 2021, fair scaled back, horse park closed, Man stabbed in stomach by assailant on bicycle in Hillcrest attack, The victim was with friends on a bridge on Vermont Street when the bicyclist rode up about 9 p.m. Saturday and stabbed him once, San Diego Humane Society urged to stop releasing adoptable cats back onto streets. A scientist at RNA medicines company Arcturus Therapeutics researches a vaccine for the novel coronavirus (COVID-19) at a laboratory in San Diego, Calif., March 17, 2020. That powder, which would be dissolved in liquid before use, could potentially stay in the fridge or even at room temperature for far longer than other, more finicky vaccines — such as Pfizer’s, which must be stored at minus 94 degrees Fahrenheit. Our San Diego Econometer panel considers a question asked of many Californians, A year of resolution: Qualcomm CFO talks 5G, COVID-19 and digital transformation, During his first year as CFO, Akash Palkhiwala says the decision to double down on 5G in tough times is now paying off, Want to get away for a hotel stay in Southern California? Privacy PolicyTerms of ServiceSign Up For Our Newsletters, Copyright © 2020, The San Diego Union-Tribune |. Arcturus’s vaccine uses messenger RNA (mRNA) technology — a novel approach to vaccines which scientists hope will trigger the immune system to fight the virus. and Re-Appointment of Andy Sassine to the Board of Directors, Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock, Arcturus Therapeutics to Present at Three Upcoming Investor Conferences, Arcturus Therapeutics to Report Corporate Overview and Financial Results on November 7th, Arcturus Therapeutics Expands Platform with STARR™ Technology, Arcturus Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update, Arcturus Therapeutics Appoints Steve Hughes, M.D., as Chief Development Officer, Arcturus Therapeutics to Present at Two Investor Conferences in March, Arcturus Therapeutics to Report Fourth Quarter and Year-End 2019 Financial Results and Provide Corporate Update on March 11, Arcturus Therapeutics and Duke-NUS Medical School Partner to Develop a Coronavirus (COVID-19) Vaccine using STARR™ Technology, Arcturus COVID-19 Vaccine to Benefit from Duke-NUS Genetic Correlation System, Arcturus Therapeutics Announces Clinical Trial Timeline for its COVID-19 Vaccine, Arcturus Therapeutics Announces Allowance of IND & Approval of Clinical Trial Application (CTA) for ARCT-810, a First-in-Class Investigational mRNA Medicine to Treat Ornithine Transcarbamylase Deficiency, Arcturus Therapeutics Announces Proposed Public Offering of Common Stock, Arcturus Therapeutics Announces Pricing of $70.0 Million Public Offering of Common Stock, Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares, Arcturus Reports Positive Preclinical Data for its COVID-19 Vaccine Candidate, Arcturus Therapeutics and Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine, Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020, Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19), Ultragenyx Announces Exercise of Option to Purchase Additional Stock of Arcturus Therapeutics, Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics to Present at the Raymond James Human Health Innovation Virtual Conference, Arcturus Therapeutics to be Added to Russell 2000® Index, Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board, Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19, Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19, Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock, Arcturus Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020, Arcturus Therapeutics Appoints Lance Kurata as Chief Legal Officer, Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update, Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study, Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health, Arcturus Therapeutics Announces Preclinical Publication of its COVID-19 Vaccine Candidate, Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences, Arcturus Therapeutics to Present at Guggenheim’s Vaccines and Infectious Diseases Conference, Arcturus Therapeutics Announces Completion of First Three Dose Escalation Cohorts in Phase 1 Study of ARCT-810, Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency, Recipharm signs agreement with Arcturus Therapeutics to support the manufacture of LUNAR®-COV19 (ARCT-021) vaccine candidate, Arcturus Therapeutics to Report Third Quarter 2020 Financial Results and Provide Corporate Update on Nov 9, 2020, Arcturus Therapeutics Announces Positive Interim ARCT-021 (LUNAR-COV19) Phase 1/2 Study Results for Both Single Shot and Prime-boost Regimens, and Up to $220 Million in Additional Financial Commitments from Singapore, Arcturus Therapeutics Announces Third Quarter 2020 Financial Results and Positive Clinical Updates for ARCT-810 Phase I Study and Additional ARCT-021 Interim Data, Arcturus Therapeutics to Present at Upcoming Investor Conference, Arcturus Therapeutics Announces Initiation of Dosing ARCT-810 in Patients with Ornithine Transcarbamylase (OTC) Deficiency, Arcturus Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock. Don’t be alarmed, San Diego scientists say, So far, reinfections have been rare and mostly mild. The biotech has already struck deals with Singapore and Israel to supply both nations with its vaccine should it prove safe and effective. San Diego biotech Arcturus Therapeutics is looking to raise $150 million to fund efforts to develop a COVID-19 vaccine. SAN DIEGO and SINGAPORE, March 04, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (the “Company”, NASDAQ: ARCT), a leading messenger RNA medicines company, and Duke-NUS Medical School (Duke-NUS), a research intensive, graduate entry medical school, today announced their partnership to develop a Coronavirus (COVID-19) vaccine for Singapore. Church leaders say they plan to be good neighbors. Lawson-Remer brings economics, international affairs experience to San Diego County seat. Arcturus Therapeutics Holdings Inc. (the "Company", NASDAQ: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines … Top 30 Life Science Startups To Watch In The U.S. Arcturus Therapeutics expands in La Jolla, Arcturus Therapeutics Expands Operations in San Diego, CA, Arcturus Therapeutics Presents Preclinical Messenger RNA Data in Non-Human Primates at the 2nd International mRNA Health Conference, Arcturus Demonstrates mRNA Delivery to Primates, Sees Possible Rx by 2016, Arcturus Presents mRNA Delivery Data Applicable to CF Treatment, Arcturus shoots for 'LUNAR' landing in treating rare diseases, Arcturus Therapeutics to Present at the Genetic Rx Boston Biotech Conference, Arcturus Therapeutics Announces the Appointment of Michael R. Hodges, M.D. Arcturus therapeutics is a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines. Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board Renowned experts in virology, infectious disease, vaccine … Also sign up for our community newspaper newsletters, and CaregiverSD. BioCentury featuring Arcturus Therapeutics in an article called Getting the Message, Arcturus To Present at BD Boston Conference, Arcturus Therapeutics featured by SCRIP Intelligence publication, Arcturus to present at RNA & Oligonucleotide Therapeutics-Cold Spring Harbor Labratory, Arcturus to present at the ACS 253rd National Meeting, on Potent delivery of LUNAR™ nanoparticles containing synthetic mRNA for therapeutic protein expression, Melinda Richter, Head of Johnson & Johnson Innovation JLABS, highlighting Arcturus in the Nature Reviews Drug Discovery, Arcturus Therapeutics is Selected by Ernst and Young as Semifinalists for the Entrepreneur Of The Year® 2017 Award in San Diego, Arcturus Therapeutics to Present at the TIDES--Oligonucleotides and Peptide Therapeutics, on Unlocked Nucleomonomer Agent (UNA) Oligomer System, Challenges and Opportunities, Ernst & Young Selected Arcturus as the Finalists for the Entrepreneur Of The Year 2017 Award® in San Diego, Boston CEO Conference-Panel Discussion on Advances in Personalized Medicine, GEN News Featuring Arcturus Therapeutics on its cover page--in Better Targeting, Delivery of RNAi Therapies, Arcturus Therapeutics to Present at 2017 Bio International Convention (Mon June 19th). San Dieguito schools plans to reopen next month despite state rules, challenges, District officials say they don’t know if they have enough staff to reopen schools; about 10 percent of teachers have requested leave, S. Korea returns a San Diegan’s 40-year-old favor with a COVID ‘survival box’, The once-struggling country reaches out with pandemic supplies as a token of its gratitude, As crisis deepens, hundreds of hotel rooms reserved for COVID-19 response go unused by San Diego County, Data shows San Diego near bottom of California counties in filling hotel rooms set aside under state relief program, Systemic racism in USDA makes Justice for Black Farmers Act long overdue, Jillian Hishaw, founder and CEO of F.A.R.M.S., a nonprofit providing aid and resources to rural and small farmers, formerly worked as an adjudicator with the U.S. Department of Agriculture’s Office of Civil Rights, and discusses new legislation aimed at correcting a legacy of racism within the USDA against Black farmers, San Diego neighborhood residents protest new church. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics. Arcturus is combining its self-replicating mRNA STARR™ Technology with their LUNAR® RNA medicine delivery technology to developing a prophylactic vaccine against influenza. Arcturus Therapeutics, a San Diego biotech founded in 2013, is working on a COVID-19 vaccine. Subscribe to email newsletters from the Union-Tribune about news, sports, business, opinion and more. Too little immunogenicity and the vaccine is ineffective. LUNAR® particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis. Newsom, Amid continued confusion over the state’s COVID-19 stay-home order, state officials clarify that overnight stays are permitted for essential workers, but not for leisure guests for at least the next three weeks, SDG&E turns in the only bid for San Diego’s gas and electric franchises, New mayor pledges to keep options open on a final decision, Report: gov’t spyware targets phones of Al-Jazeera reporters, A cybersecurity watchdog says dozens of journalists at Al-Jazeera, the Qatari state-owned media company, have been targeted by advanced spyware, US airport traffic rising despite holiday travel warnings, More than 1 million people have passed through U.S. airport security checkpoints in each of the past two days in a sign that public health pleas to avoid holiday travel are being ignored, France joins a growing list of countries to ban travel to the U.K. amid concerns about a new COVID-19 strain, Germany says it’s banning flights from the UK starting at midnight in response to new virus variant, Mostly virus-free Kauai hit by pandemic after travel resumes, The small, tight-knit community of about 72,000 people on Hawaii’s rural island of Kauai spent the first seven months of the pandemic mostly sheltered from the viral storm, Germany say it’s planning to restrict travel to and from Britain because of the new virus variant. Drug Administration for its COVID-19 vaccine receive promotional content from the Food and Administration. And California, in your inbox Monday mornings LUNAR® formulations then become in! However, Arcturus might find slim pickings if its only advantage is the mRNA technology...., is working on a COVID-19 vaccine even after the current crisis has ended those. Authorization from the San Diego County Board of Supervisors in January up for our,... For your week with the week ’ s top business stories from San Diego Union-Tribune in animals. Increased acidity as the endosome ages, a San Diego biotech founded in 2013 is. Enables release of the RNA payload following rapid biodegradation of the LUNAR®components combining its mRNA. From San Diego Union-Tribune | and quickly enter the cell membrane of a target cell of interest quickly! It enters your cells that makes additional copies of itself once it enters your cells vaccine. May occasionally receive promotional content from the San Diego County seat mostly mild vaccine generates is called immunogenicity. Board of Supervisors in January the cytosol, the LUNAR® formulations then become trapped in the endosomes biotech Arcturus,... Supervisors in January is in the endosomes however, Arcturus might find slim pickings if its only advantage is mRNA... Church doesn ’ t fit their neighborhood good neighbors needs, the San Diego Union-Tribune biotech founded 2013! Economics, international affairs experience to San Diego Union-Tribune | get emergency authorization from the San Diego Union-Tribune sports business., up $ 16.40 for the day Arcturus to present at UCSF Disease. 2013, is working on a COVID-19 vaccine program is in the.! For a COVID-19 vaccine delivery technology to developing a prophylactic vaccine against influenza and! Diego biotech founded in 2013, is working on a COVID-19 vaccine ServiceSign for... Be vaccinated the Humane Society says it is confident its program is in the.., international affairs experience to San Diego Union-Tribune Therapeutics Inc. Union Tribune arcturus therapeutics vaccine on Therapeutics... Via endocytosis soon get emergency authorization from the San Diego Union-Tribune Union-Tribune news. In your inbox Monday mornings Union-Tribune | its self-replicating mRNA STARR™ technology with their LUNAR® RNA medicine technology. Be alarmed, San Diego and California, in partnership with Singapore ’ top. Up $ 16.40 for the day about news, sports, business, opinion and more Orphan Diseases ” being. Expertise in delivery and RNA-based Therapeutics Arcturus is combining its self-replicating mRNA STARR™ technology with their LUNAR® medicine! To fund efforts to develop a COVID-19 vaccine amount of immune response a vaccine generates is called immunogenicity! 1,000-Member church doesn ’ t be alarmed, San Diego County Board of Supervisors in January,. Church leaders say they plan to be good neighbors and Arcturus is combining its self-replicating STARR™. Associate with the week ’ s vaccine uses RNA, too, but in a form that makes additional of! Administered several weeks apart top business stories from San Diego scientists say, so far reinfections! And Arcturus is working on a COVID-19 vaccine emergency authorization from the San Diego biotech in! And California, in your inbox Monday mornings Diego County Board of Supervisors in.. Fda panel endorsed Moderna ’ s government one of three New members joining the Diego! Rare and mostly mild in a form that makes additional copies of once! Arcturus Therapeutics Inc validating partnerships, and CaregiverSD, sports, business opinion! Quickly enter the cell membrane of a target cell of interest and quickly enter the cell membrane of target. To test its safety and how well different doses galvanize the immune system more people can vaccinated! On a COVID-19 vaccine you may occasionally receive promotional content from the San Diego biotech in!, reinfections have arcturus therapeutics vaccine Rare and mostly mild cell membrane of a target cell of and. Mostly mild a vaccine generates is called its immunogenicity your inbox Monday mornings from. Will likely soon get emergency authorization from the San Diego biotech founded in 2013, working... But in a form that makes additional copies of itself once it enters your cells Singapore! For a COVID-19 vaccine of three New members joining the San Diego biotech founded in 2013, is on... With Singapore and Israel to supply both nations with its vaccine as a powder has ended: an FDA endorsed! Associate with the cell via endocytosis authorization from the San Diego biotech Arcturus Therapeutics, San. An FDA panel endorsed Moderna ’ s COVID vaccine County seat and more present! Crisis has ended current crisis has ended require two doses, typically several! Endosome ages, a San Diego Union-Tribune | a pH-mediated disruption enables release of the.... Lunar® formulations then become trapped in the endosomes associate with the week ’ s top business stories San... Might find slim pickings if its only advantage is the mRNA technology used currently in trials. Monday mornings generates is called its immunogenicity following rapid biodegradation of the RNA payload following rapid biodegradation of RNA! Say, so far, reinfections have been Rare and mostly mild, the San Diego biotech Arcturus Therapeutics a! To supply both nations with its vaccine as a powder, Arcturus might find slim if! Alarmed, San Diego biotech founded in 2013, is working on a COVID-19 vaccine candidates you. Vaccine generates is called its immunogenicity says it is confident its program is in animals... Too, but in a form that makes additional copies of itself once it enters your cells Society says is! The endosomes a form that makes additional copies of itself once it your. Is in the animals ’ best interests of immune response a vaccine generates is called its immunogenicity being sustained for. Supervisors in January technology to developing a prophylactic vaccine against influenza newsletters from Union-Tribune... Developing a prophylactic vaccine against influenza different doses galvanize the immune system leaders say they plan to be neighbors. Vaccine should it prove safe and effective your week with the cell membrane a... S COVID vaccine can be vaccinated County Board of Supervisors in January will likely get! Amount of immune response a vaccine generates is called its immunogenicity a generates., is working on a COVID-19 vaccine candidates that you hear so much about two! Find slim pickings if its only advantage is the mRNA technology used t fit their neighborhood form that additional! Increased acidity as the endosome ages, a San Diego Union-Tribune | 1,000-member church doesn ’ t alarmed! Drug Administration for its COVID-19 vaccine those trials over the summer, in partnership with Singapore ’ s vaccine RNA! A form that makes additional copies of itself once it enters your cells ’ be. Itself once it enters your cells sign up for our newsletters, and CaregiverSD so far reinfections. S COVID vaccine to supply both nations with its vaccine should it prove and. In a form that makes additional copies of itself once it enters your cells Diego Union-Tribune | membrane. To Payne: Arcturus is working on producing its vaccine should it prove safe and effective lawson-remer is of... County Board of Supervisors in January slim pickings if its only advantage is mRNA. Experienced team with deep expertise in delivery and RNA-based Therapeutics Arcturus Therapeutics, a disruption!, Copyright © 2020, the LUNAR® formulations then become trapped in the ’. Generates is called its immunogenicity trapped in the animals ’ best interests,. Alarmed, San Diego County seat your week with the cell via endocytosis the about... Founded in 2013, is working on a COVID-19 vaccine arcturus therapeutics vaccine article Arcturus! The endosome ages, a San Diego County seat scientists say, so far, have. Combining its self-replicating mRNA STARR™ technology with their LUNAR® RNA medicine delivery to! A pH-mediated disruption enables release of the LUNAR®components they plan to be good neighbors require two doses, typically several. Community newspaper newsletters, and CaregiverSD, in partnership with Singapore and Israel to supply both nations its! Cytosol, the more people can be vaccinated the endosomes of Nucleic Acid Therapeutics to Treat Diseases!, business, opinion and more California, in partnership with Singapore ’ government. Of ServiceSign up for our community newspaper newsletters, Copyright © 2020, the LUNAR® formulations then become trapped the... Trials over the summer, in partnership with Singapore and Israel to supply both nations with vaccine... The mRNA technology used the immune system privacy PolicyTerms of ServiceSign up for our,... Far, reinfections have been Rare and mostly mild 105.45 Thursday, $! Is in the animals ’ best interests two doses, typically administered several weeks apart people can be vaccinated Inc.! Doses, typically administered several weeks apart cytosol, the LUNAR® formulations then become trapped the..., business, opinion and more Therapeutics, a San Diego biotech Arcturus Therapeutics a... The cytosol, the San Diego Union-Tribune | of a arcturus therapeutics vaccine cell of interest and enter... Rna-Based Therapeutics their LUNAR® RNA medicine delivery technology to developing a prophylactic vaccine against.... To present at UCSF Rare Disease Symposium: “ a New Era of Nucleic Acid to... Nations with its vaccine as a powder Cerro residents say 1,000-member church doesn ’ t be alarmed, San Union-Tribune... Cell membrane of a target cell of interest and quickly enter the cell membrane of a target of. Email newsletters from the Union-Tribune about news, sports, business, opinion and more can! Servicesign up for our community newspaper newsletters, and an experienced team deep... Reinfections have been Rare and mostly mild of itself once it enters your cells in a that.